logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onCalendarPlatformsJob offersTools
 

News

boto imprimir
Date: 18/04/2013

Identified as responsible for breast and ovarian hereditary cancer three BRCA1 mutations

This study will improve genetic counselling and clinical monitoring of patients and families who present these variants


Researchers of the hereditary cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) conducted a functional and structural study of seven missense variants of the BRCA1 gene concluding that three of these variants are pathogenic, linked to the risk of suffering breast or ovarian cancer. The study has been published in the journal PLoS One

 

The classification of these three variants will improve genetic counseling of patients and families who have these mutations and will serve to personalize the treatment.

 

Mutations in BRCA1 gene


Mutations in BRCA1 confer a high risk of developing breast or ovarian cancer. A woman carrying a mutation in this gene has a risk of developing breast cancer between 40% and 90% and of developing ovarian cancer between 20% and 70%.

 

According to the researcher Conxi Lázaro, "now we know a lot of genetic alterations in BRCA1 that are clearly pathogenic alterations, neutral alterations and sequence polymorphisms, but genetic diagnostic studies also identify changes in the DNA sequence which we don't  know its biological significance."

 

For the researcher, finding out the biological consequences of these missense variants is "a technological challenge, not only in breast cancer but in the field of genetic diagnostics in general."

 

Study of seven missense variants

 

The study analyzes seven BRCA1 gene variants from a structural and functional standpoint. Structural analysis is a theoric-computational analysis and compares the three-dimensional structure of normal protein with the analyzed changes. The researchers conclude that three of the seven variants analyzed modify the structure of the protein.

 

"In the functional study," said the researcher, "we analyzed in vitro one of the key functions of BRCA1: regulation of transcription. The analysis involves the generation of mutants of all variants in specific vectors to assess the transcriptional activity of the mutant compared to the control activity of the wild-type sequence of the BRCA1 gene.

 

From this analysis, the researchers concluded that three of the seven variants of unknown biological significance are actually pathogenic and will serve clinicians to a better genetic counseling to patients and families that present these variants, allowing personalized risk assessment cancer.

 

Genetic counselling


The knowledge of the clinical effects of these mutations will allow to offer genetic counselling to families. "To the individuals who carry the mutation we can offer a comprehensive clinical monitoring and the possibility of reproductive options, such as prenatal or preimplantation diagnosis", said Lazaro, "while members of the family who doesn't have the mutation can be considered as general population".

 

The work was done in collaboration with researchers from the Institute of Biomedical Research of Barcelona (IRBB) and Epidemiology Program Lee Moffitt Cancer Center & Cancer Research Institute in Florida, the United States and has been funded by the Institute of Salud Carlos III (FIS projects, PFIS and RTICC), Generalitat de Catalunya (SGR) and the Spanish Association against Cancer.

 

Article reference

 

Quiles F., Fernández-Rodríguez J., Mosca R, Feliubadaló L., Tornero E, Brunet J., Blanco I., Capella G., Pujana M.A., Aloy P., Monteiro A., and Lázaro C.. (2013)  Functional and structural analysis of C-terminal BRCA1 missense variants.  PLoS ONE 8(4): e61302. doi: 10.1371/journal.pone.0061302





foto Researchers Juana Fernández, Conxi Lázaro and Lídia Feliubadaló
Researchers Juana Fernández, Conxi Lázaro and Lídia Feliubadaló

Share/Bookmark
 
© 2014 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




You have not yet answered the internal personal satisfaction survey. It will not take you more than five minutes. Your opinion is very important to improve IDIBELL.

Do you want to complete the survey now?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No